What if you could skip the BE study entirely? With BCS-based biowaivers, you can. 💊

The Biopharmaceutics Classification System (BCS) allows sponsors to waive in vivo bioequivalence studies for certain oral drug products, replacing them with in vitro dissolution data and, increasingly, PBPK absorption modeling. 📈 For BCS Class I and III drugs, biowaivers are well established. But the real opportunity lies in BCS Class II, where PBPK modeling can build the mechanistic, regulatory-grade case for extending a biowaiver where a traditional study would otherwise be required.

FDA, European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada | Santé Canada, Therapeutic Goods Administration (TGA), ANVISA and others, all accept PBPK absorption modeling as part of the totality of evidence supporting BCS-based biowaiver applications and with ICH M15 now globally harmonised, this acceptance is only expanding. When built correctly with in silico, with validated dissolution inputs, appropriate virtual population strategies, and a well-documented model rationale, this approach can eliminate the need for costly and time-consuming human BE studies, while generating evidence that is scientifically robust and fully aligned with regulatory expectations.

At InSilicoMinds, we help generic companies build PBPK-supported biowaiver strategies across BCS classes, from model development and dissolution integration to full regulatory dossier support. If a BE study is slowing down your ANDA timeline, let’s talk. 🤝

📩 info@insilicominds.com | 🌐 insilicominds.com

Link: https://www.linkedin.com/posts/insilicominds_biowaivers-bcsbiowaiver-bioequivalence-activity-7480524838906998785-ZbFj?utm_source=share&utm_medium=member_desktop&rcm=ACoAADwxO4EBoUDYrVD3Nd3qEIQA_HncV2kdfTM